GlassScriptPhysician profile
Christina Shohatee
NPI 1912586967
$1,744.60
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $398 · 2022: $759 · 2023: $445 · 2024: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $433.19 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Ironwood Pharmaceuticals, INC | $264.11 | 2021-2023 | Linzess |
| Lilly USA, LLC | $201.90 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.88 | 2021-2023 | Jardiance |
| Abbvie INC. | $103.59 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.60 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.17 | 2021-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $60.33 | 2022-2023 | |
| Pfizer INC. | $49.30 | 2021-2022 | |
| Amgen INC. | $48.41 | 2022-2023 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $47.40 | 2021-2022 | |
| Amarin Pharma, INC. | $41.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.96 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $24.70 | 2021 | |
| Phadia US INC. | $19.34 | 2023 | Immunocap |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.04 | 2023 | Dificid |
| Exact Sciences Corporation | $18.56 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $16.64 | 2022 | |
| Glaxosmithkline, LLC. | $16.18 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.82 | 2021 | |
| Redhill Biopharma INC. | $13.81 | 2021 | |
| Abbott Laboratories | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Shohatee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.